AdvanSix
AdvanSix's revenue rose 0.3% to $1.5 billion in fiscal 2025. Its net margin was 3.2%, up from 2.9% a year earlier. Free cash flow was $6 million, up 279.5%. It paid out $19 million in dividends and buybacks, 293% of free cash flow. The diluted share count rose 0.3%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What AdvanSix does
AdvanSix is a U.S. chemical maker that Honeywell spun off in 2016. It runs five manufacturing plants in the United States and sells materials used in building and construction, farming, plastics, packaging, paints, adhesives and electronics.
It has three product groups. Nylon solutions are Nylon 6 resin, which customers turn into fibers, plastics and films for carpets, car parts, sports clothing and food packaging, and caprolactam, the main ingredient of that resin. Plant nutrients are mostly ammonium sulfate, a fertilizer that supplies nitrogen and sulfur, sold mainly to distributors, farm cooperatives and retailers in North and South America. Chemical intermediates are products such as acetone, phenol and cyclohexanone, which go into solvents, paints, coatings, adhesives and herbicides.
Most of this comes from its Hopewell, Virginia plant, where one process feeds the next. The company says the plant is the world's largest single-site producer of ammonium sulfate and one of the largest of caprolactam. At the end of 2025 it employed about 1,410 people.
Its biggest risks, as it describes them
- Swings in the industries it sells to, which can sharply change its cash flows.
- Higher costs for raw materials such as cumene, natural gas and sulfur that it cannot pass on to customers.
- Downtime or accidents at its few production plants, including hazards of making and shipping chemicals.
- Losing one or more of its significant customers.
- Needing large amounts of capital for its plants and growth projects, which may not be available on good terms.
Income statement
From fiscal 2016 to 2025, earnings per share grew 5.4% a year and net income 4.2% a year, as buybacks cut the share count by 10%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 15 | 31 | 30 | 20 | 20 |
| Debt incl. finance leases | 136 | 117 | 2 | 2 | 2 |
| Net debt (negative means net cash) | 121 | 86 | −28 | −17 | −18 |
| Net debt to EBITDA | 0.5x | 0.3x | −0.2x | −0.1x | −0.1x |
| Debt to equity | 0.2x | 0.2x | 0.0x | 0.0x | 0.0x |
| Interest coverage | 42.5x | 101.8x | 10.8x | 5.2x | 9.1x |
| Current ratio | 1.1x | 1.1x | 1.2x | 1.1x | 1.1x |
| Quick ratio | 0.7x | 0.6x | 0.6x | 0.5x | 0.5x |
Cash flow
Projections
Project AdvanSix's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What AdvanSix says to expect
- Full year 2026: capital expenditures
Now expect Capital Expenditures of approximately $90 million in 2026 versus $116 million in 2025, reflecting risk-based prioritization of base investments and enterprise programs with continued progression of growth programs including SUSTAIN
- Full year 2026: plant turnarounds
Continue to expect pre-tax income impact of plant turnarounds to be approximately $17 million in 2026 versus $25 million in 2025
Insider trades
No officer, director or 10% owner of AdvanSix reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 4 of 9 | 6 of 9 |
| Rule of 40 | −20.5% | −0.9% | 0.7% |
| Altman Z'' | 2.95 | 2.64 | 2.66 |
| Accruals ratio | −4.2% | −5.9% | −4.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Pass | Pass | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | 6 of 9 | 4 of 9 | 6 of 9 |
Compare
Put AdvanSix side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| AdvanSix | FY25 | 0.3% | — | 0.4% | 7.1% | −0.1x | 6 | |
| Sensient Technologies | FY25 | 3.5% | 12.8% | 2.4% | 8.9% | 2.5x | 6 | Compare |
| Innospec | FY25 | −3.6% | 7.3% | 5.0% | 11.1% | −1.7x | 6 | Compare |
| Quaker Chemical | FY25 | 2.7% | 2.8% | 4.3% | 1.3% | 6.1x | 5 | Compare |
| Ingevity | FY25 | −2.7% | 35.9% | 23.4% | 24.6% | 2.1x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1,192 | 1,475 | 1,515 | 1,297 | 1,158 | 1,685 | 1,946 | 1,534 | 1,518 | 1,522 |
| Revenue growth | −10.4% | 23.8% | 2.7% | −14.4% | −10.8% | 45.5% | 15.5% | −21.2% | −1.1% | 0.3% |
| Gross profit | 108 | 227 | 174 | 136 | 134 | 274 | 314 | 165 | 153 | 165 |
| Research and development | 14 | 13 | 15 | 14 | 12 | 14 | 12 | 10 | 9 | 9 |
| Operating income | — | — | — | — | — | — | — | — | — | — |
| Net income | 34 | 147 | 66 | 41 | 46 | 140 | 172 | 55 | 44 | 49 |
| Diluted EPS (US$) | 1.12 | 4.72 | 2.14 | 1.43 | 1.64 | 4.81 | 5.92 | 1.95 | 1.62 | 1.80 |
| Diluted shares (millions) | 30 | 31 | 31 | 29 | 28 | 29 | 29 | 28 | 27 | 27 |
| Cash flow | ||||||||||
| Cash from operations | 114 | 135 | 173 | 120 | 112 | 219 | 274 | 118 | 135 | 123 |
| Capital expenditure | 84 | 86 | 109 | 150 | 83 | 57 | 89 | 107 | 134 | 116 |
| Free cash flow | 30 | 48 | 64 | −30 | 29 | 162 | 184 | 10 | 2 | 6 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 4 | 15 | 17 | 17 | 17 |
| Share buybacks | 0 | 0 | 38 | 62 | 1 | 1 | 34 | 46 | 10 | 2 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 10 | 98 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 8 | 10 | 8 | 5 | 11 | 10 | 8 | 8 | 7 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 14 | 55 | 10 | 7 | 11 | 15 | 31 | 30 | 20 | 20 |
| Debt incl. finance leases | 265 | 248 | 200 | 298 | 276 | 136 | 117 | 2 | 2 | 2 |
| Total assets | 905 | 1,050 | 1,035 | 1,236 | 1,263 | 1,312 | 1,495 | 1,496 | 1,595 | 1,706 |
| Total liabilities | 690 | 674 | 614 | 835 | 819 | 711 | 757 | 757 | 820 | 891 |
| Shareholders' equity | 215 | 376 | 420 | 401 | 444 | 601 | 738 | 739 | 775 | 815 |
| Margins and ratios | ||||||||||
| Gross margin | 9.0% | 15.4% | 11.5% | 10.4% | 11.6% | 16.3% | 16.2% | 10.8% | 10.1% | 10.8% |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | 2.9% | 9.9% | 4.4% | 3.2% | 4.0% | 8.3% | 8.8% | 3.6% | 2.9% | 3.2% |
| Free cash flow margin | 2.5% | 3.3% | 4.2% | −2.3% | 2.5% | 9.6% | 9.5% | 0.7% | 0.1% | 0.4% |
| Rule of 40 (growth + FCF margin) | −7.9% | 27.1% | 6.9% | −16.7% | −8.2% | 55.1% | 25.0% | −20.5% | −0.9% | 0.7% |
| Return on capital | — | 29.3% | 12.0% | 7.0% | 7.5% | 20.0% | 22.4% | 7.8% | 7.4% | 7.1% |
| Return on equity | 9.8% | 49.6% | 16.6% | 10.1% | 10.9% | 26.8% | 25.7% | 7.4% | 5.8% | 6.2% |
| Return on assets | 3.9% | 15.0% | 6.3% | 3.6% | 3.7% | 10.9% | 12.2% | 3.6% | 2.9% | 3.0% |
| Net debt to EBITDA | 2.6x | 1.0x | 1.3x | 2.5x | 2.1x | 0.5x | 0.3x | −0.2x | −0.1x | −0.1x |